Skip to content
MedsAcross

Fixed-dose combination

Polymyxin b and Trimethoprim

Also known as polymyxin b sulfate, trimethoprim, trimethoprim sulfate
Available on request
Presentations
2
Brands
0
Manufacturers
0
Available from stock
0

Polymyxin b and Trimethoprim is a fixed-dose combination of a dihydrofolate reductase inhibitor antibacterial and a polymyxin-class antibacterial. It is available as eye drops and ophthalmic solution. MedsAcross supplies Polymyxin b and Trimethoprim for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Key facts

Pharmacological class
Dihydrofolate Reductase Inhibitor Antibacterial, Polymyxin-class Antibacterial, Cytochrome P450 2C8 Inhibitors, Dihydrofolate Reductase Inhibitors, Organic Cation Transporter 2 Inhibitors
US FDA first approval
20 October 1988
EU status
Not recorded
Orphan designation
Not recorded
WHO essential medicine
Not recorded
India (CDSCO)
Not yet confirmed against CDSCO approval lists
Routes
Ophthalmic
Dosage forms
Eye drops, Ophthalmic solution
Fixed-dose combination of
Polymyxin b, Trimethoprim

Clinical information

From the regulator-approved product information. Each section names its source.

Uses

Polymyxin B sulfate and trimethoprim ophthalmic solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus viridans, Haemophilus influenzae and Pseudomonas aeruginosa. 1 1 Efficacy for this organism in this organ system was studied in fewer than 10 infections.

Source: US FDA prescribing information

Dosing overview

In mild to moderate infections, instill one drop in the affected eye(s) every 3 hours (maximum of 6 doses per day) for a period of 7 to 10 days.

Source: US FDA prescribing information

Contraindications

Polymyxin B sulfate and trimethoprim ophthalmic solution is contraindicated in patients with known hypersensitivity to any of its components.

Source: US FDA prescribing information

Warnings and precautions

NOT FOR INJECTION INTO THE EYE. If a hypersensitivity reaction to polymyxin B sulfate and trimethoprim ophthalmic solution occurs, discontinue use. Polymyxin B sulfate and trimethoprim ophthalmic solution is not indicated for the prophylaxis or treatment of ophthalmia neonatorum.

Source: US FDA prescribing information

Side effects

The most frequent adverse reaction to polymyxin B sulfate and trimethoprim ophthalmic solution is local irritation consisting of increased redness, burning, stinging, and/or itching. This may occur on instillation, within 48 hours, or at any time with extended use. There are also multiple reports of hypersensitivity reactions consisting of lid edema, itching, increased redness, tearing, and/or circumocular rash. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and anaphylaxis have been reported. Photosensitivity has been reported in patients taking oral trimethoprim.

Source: US FDA prescribing information

Storage

Store at 15°C to 25°C (59°F to 77°F). PROTECT FROM LIGHT. *Does not meet USP packaging specification for light resistance.

Source: US FDA prescribing information

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

All presentations

2 presentations of Polymyxin b and Trimethoprim, sorted by availability.

MedicineActive ingredientManufacturerRegisterAvailability
Polymyxin b and Trimethoprim 10000 units/1 mg per mL eye dropsOphthalmicGeneric namePolymyxin b and Trimethoprim—US FDAAvailable on request
Polymyxin b and Trimethoprim 10000 units/1 mg per mL ophthalmic solutionOphthalmicGeneric namePolymyxin b and Trimethoprim—US FDAAvailable on request

Regulatory status

Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.

RegisterStatusSource
US FDAFirst approved 20 October 1988Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Questions and answers

Is Polymyxin b and Trimethoprim available for export from India?

Yes, on request. MedsAcross lists 2 presentations of Polymyxin b and Trimethoprim and sources them for licensed hospitals, importers and physicians against valid import documents.

Is Polymyxin b and Trimethoprim approved by the US FDA?

Yes. The US FDA first approved Polymyxin b and Trimethoprim on 20 October 1988, according to Drugs@FDA.

Does Polymyxin b and Trimethoprim need cold chain shipping?

No listed presentation of Polymyxin b and Trimethoprim is recorded as needing a cold chain. Storage conditions are shown on each presentation page.

References

  1. Polymyxin B Sulfate and Trimethoprim prescribing information (Bausch & Lomb). U.S. National Library of Medicine, DailyMed. Retrieved 6 January 2026

Request Polymyxin b and Trimethoprim for export supply

Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.

Request a quoteRead the import guides